Clinicopathologic and prognostic parameters | Number of studies | Number of patients | Effect size | Heterogeneity | Sensitivity analysis | Publication bias | ||||
---|---|---|---|---|---|---|---|---|---|---|
OR/HR | 95%CI | p value | I-square (%) | chi-square (p) | Begg (p) | Egger (p) | ||||
Age | 3 | 146 | 1.915 | 0.959–3.826 | 0.066 | 0.0% | 0.889 | Reliable | 0.602 | 0.944 |
Gender | 3 | 146 | 0.697 | 0.364–1.335 | 0.276 | 20.6% | 0.284 | Reliable | 0.602 | 0.645 |
Tumor site | 3 | 146 | 0.709 | 0.348–1.441 | 0.342 | 0.0% | 0.960 | Reliable | 0.117 | 0.145 |
Tumor size | 3 | 146 | 1.101 | 0.235–5.157 | 0.903 | 78.6% | 0.009 | Not Reliable | 0.602 | 0.387 |
Clinical stage | 3 | 146 | 3.016 | 0.599–15.169 | 0.181 | 75.9% | 0.016 | Not Reliable | 0.602 | 0.249 |
Differentiation grade | 2 | 106 | 0.130 | 0.254–1.192 | 0.130 | 0.0% | 0.502 | NA | 0.317 | NA |
Metastasis | 3 | 146 | 2.290 | 0.185–28.348 | 0.519 | 90.1% | <0.001 | Not Reliable | 0.602 | 0.821 |
Overall survival | 3 | 146 | 3.197 | 2.054–4.976 | <0.001 | 0.0% | 0.776 | Reliable | 0.602 | 0.825 |